Analysis of lung cancer risk factors and serum tumor markers

doi:10.3877/cma.j.issn.1674-6902.2017.03.017

Abstract

Abstract:

Objective

To discuss the value of serum tumor markers in people at high risk of lung cancer and explore the detection methods of lung cancer risk factors.

Methods

230 cases were randomly selected in hospitalized patients with lung cancer risk factors from Jan 2013 to Feb 2014.70 cases with benign disease were selected as control group. Serum tumor markers were detected by electrochemiluminescence immunoassay.

Results

160 cases were diagnosed lung cancer by bronchoscope or thoracoscopy. 12 cases were diagnosed lung cancer in following 6-22 months. In the patients hospitalized due to lung nodules, 88 cases were diagnosed lung cancer and 8 cases were diagnosed lung cancer in following period.The increased levels of several serum tumor markers and serum ferritin could distinguish benign and malignant pulmonary nodule(P<0.05). Pulmonary nodule combined with highly serum ferritin detection had significant value in diagnosis lung cancer(P=0.021).

Conclusion

Highly tumor marker and serum ferritin are significant risk factors. Independent Ferritin detection is not statistically significant in benign or malignant tumor. The joint detection of serum ferritin and pulmonary nodules has clinical diagnostic value in lung cancer.

Key words: Tumor marker, Ferritin, Bronchogenic lung cancer, Risk factor, Pulmonary nodule

Yanping Li, Jun Yin. Analysis of lung cancer risk factors and serum tumor markers[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2017, 10(03): 321-324.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2017.03.017

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2017/V10/I03/321

Figures/Tables 3

References 21

1	钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-6.
2	Iqbal S, Iqbal K, Arif F. Potential lung nodules identification for characterization by variable multistep threshold and shape indices from CT images[J]. Comput Math Methods Med, 2014, 2014: 241647.
3	Son KJ, Choi KR, Lee SJ, et al. Immunogenic cell death induced by ginsenoside Rg3: significance in dendritic cell-based anti-tumor immunotherapy[J]. Immune Netw, 2016, 16(1): 75-84.
4	刘慧，李永怀，桂淑玉. 肺癌患者血清肿瘤标记物检测的临床意义及预后评估[J]. 临床肺科杂志，2014, 19(12): 2219-2222.
5	Li X, Lu J, Ren H, et al. Combining multiple serum biomarkers in tumor diagnosis: A clinical assessment[J]. Mol Clin Oncol, 2013, 1(1): 153-160.
6	Chu XY, Hou XB, Song WA, et al. Diagnostic values of SCC, CEA, Cyfra21-1 and NSE for lung Cancer in patients with suspicious pulmonary: a single center analysis[J]. Cancer Biol Ther, 2011, 11(12): 995-1000.
7	Horinouchi H. Anti-vascular endothelial growth factor therapies at the crossroads：linifanib for non-small cell lung cancer[J]. Transl Lung Cancer Res, 2016, 5(1): 78-81.
8	Cho A, Hur J, Moon YW, et al. Correlation between EGFR gene mutation, cytologic tumor markers，18F-FDG uptake in non-small cell lung cancer[J]. BMC Cancer, 2016, 16: 224-232.
9	廖美琳，周允中. 肺癌[M]. 上海：上海科学技术出版社，2013.
10	甄永生，蒙志宏，靳强. 13种肿瘤标志物联合胸部CT在周围型肺癌的诊断价值[J]. 河北医药，2014, 36(24): 3747-3749.
11	Carpagnano GE, Lacedonia D, Palladino GP, et al. Could exhaled ferritin and SOD be used as markers for lung cancer and prognosis prediction purposes[J]. Eur J Clin Invest, 2012, 42(5): 478-486.
12	Cheng Z, Dai LL, Song YN, et al. Regulatory effect of iron regulatory protein-2 on iron metabolism in lung cancer[J]. Genet Mol Res, 2014, 13(3): 5514-5522.
13	Fonseca-Nunes A, Jakszyn P, Agudo A. Iron and cancer Risk-A systematic review and Meta-analysis of the epidemiological evidence[J]. Cancer Epidemiol Biomarkers Prev, 2014, 23(1): 12-31.
14	Shi HB, Li XD, Jiang JT, et al. Serum ferritin is elevated in advanced non-small cell lung cancer patients and is associated with efficacy of platinum-based chemotherapy[J]. J Cancer Res Ther, 2014, 10(3): 681-685.
15	Ji M, Li XD, Shi HB, et al. Clinical significance of serum ferritin in elderly patients with primary lung carcinoma[J]. Tumour Biol, 2014, 35(10): 10195-10199.
16	袁海云，夏旭，胡宁东. 孤立性肺结节患者临床预测模型的对比分析[J/CD]. 中华肺部疾病杂志(电子版), 2013, 10(2): 444-446.
17	邓光琴. 肺癌患者血清铁蛋白检测的临床意义[J]. 检验医学与临床，2006, 3(3): 130-131.
18	Fenchel K, Sellmann L, Dempke WC. Overall survival in non-small cell lung cancer-what is clinically meaningful？[J]. Transl Lung Cancer Res, 2016, 5(1): 115-119.
19	Codony-Servat J, Verlicchi A, Rosell R. Cancer Stem cells in small cell lung cancer[J]. Transl Lung Cancer Res, 2016, 5(1): 16-25.
20	Pircher A, Jöhrer K, Kocher F, et al. Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies[J]. Oncotarget, 2016, 7(15): 20109-20123.
21	黄晓珠，包勇. 痰分子标志物在肺癌早期诊断中的研究进展[J/CD]. 中华肺部疾病杂志(电子版), 2015, 8(1): 99-102.

临床资料及观测指标		肺癌组(含后期随访确诊病例)(n＝172)	非肺癌组(n＝58)	统计量	P值
年龄		?	?	?	?
?	<40岁	?	3	4	3.97±0.18
?	40 ～65岁	88	32	85.36±11.929	?
?	>65岁	81	22	56.96±29.262	?
性别		?	?	?	0.007
?	男	134	39	42.13±17.056	?
?	女	38	19	37.11±4.047	?
有吸烟史		115	22	107.11	0.000
有胸腔积液		66	16	112.37	0.139
胸部CT提示结节/实性占位		96	32	115.31	0.932
癌胚抗原(CEA)增高		124	17	103.09	0.000
细胞角蛋白19片段(CYFRA21-1)增高		98	13	105.48	0.000
神经特异性烯醇化酶(NSE)增高		67	12	110.20	0.011
鳞状上皮细胞癌抗原(SCC)增高		45	8	111.91	0.054
肿瘤标志物		?	?	?	0.000
?	正常	33	31	142.2	?
?	1项增高	26	12	122.82	?
?	2项增高	34	7	106.13	?
?	3项及以上增高	79	8	97.07	?
铁蛋白增高		101	22	109.47	0.006

临床资料及观测指标		肺癌组(含后期随访确诊病例)(n＝172)	非肺癌组(n＝58)	统计量	P值
年龄		?	?	?	?
?	<40岁	?	3	4	3.97±0.18
?	40 ～65岁	88	32	85.36±11.929	?
?	>65岁	81	22	56.96±29.262	?
性别		?	?	?	0.007
?	男	134	39	42.13±17.056	?
?	女	38	19	37.11±4.047	?
有吸烟史		115	22	107.11	0.000
有胸腔积液		66	16	112.37	0.139
胸部CT提示结节/实性占位		96	32	115.31	0.932
癌胚抗原(CEA)增高		124	17	103.09	0.000
细胞角蛋白19片段(CYFRA21-1)增高		98	13	105.48	0.000
神经特异性烯醇化酶(NSE)增高		67	12	110.20	0.011
鳞状上皮细胞癌抗原(SCC)增高		45	8	111.91	0.054
肿瘤标志物		?	?	?	0.000
?	正常	33	31	142.2	?
?	1项增高	26	12	122.82	?
?	2项增高	34	7	106.13	?
?	3项及以上增高	79	8	97.07	?
铁蛋白增高		101	22	109.47	0.006

诊断方法	肺癌组检出例数	非肺癌组检出例数	灵敏度(%)	特异度(%)	阳性似然比	阴性似然比
肿标正常＋铁蛋白增高	10	18	33.3	47.1	0.63	1.42
1项增高＋铁蛋白增高	17	3	70.8	78.6	3.31	0.37
2项增高＋铁蛋白增高	25	2	78.1	77.8	3.52	0.28
3项增高＋铁蛋白增高	45	3	60.8	76.9	2.64	0.51
占位病变＋铁蛋白增高	57	17	64.8	57.5	1.52	0.61
无占位＋铁蛋白增高	40	9	55.6	70.0	1.85	0.63

诊断方法	肺癌组检出例数	非肺癌组检出例数	灵敏度(%)	特异度(%)	阳性似然比	阴性似然比
肿标正常＋铁蛋白增高	10	18	33.3	47.1	0.63	1.42
1项增高＋铁蛋白增高	17	3	70.8	78.6	3.31	0.37
2项增高＋铁蛋白增高	25	2	78.1	77.8	3.52	0.28
3项增高＋铁蛋白增高	45	3	60.8	76.9	2.64	0.51
占位病变＋铁蛋白增高	57	17	64.8	57.5	1.52	0.61
无占位＋铁蛋白增高	40	9	55.6	70.0	1.85	0.63

标志物	变量系数	标准误	统计量	P值	OR值	OR的95%CI
肿瘤标志物	0.535	0.135	15.641	0.000	1.708	1.31～2.227
铁蛋白	0.849	0.323	6.909	0.009	2.337	1.241～4.402

Please choose a citation manager

Content to export